Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 monthsDivestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market NXT-41x clearance expected in the first half of 2027 GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWI ...